Molecular Mechanism of an Exporter-like ABC Importer YbtPQ

NIH RePORTER · NIH · R01 · $499,200 · view on reporter.nih.gov ↗

Abstract

Bacterial infections pose one of the most significant global public health challenges, exacerbated by the emergence of antibiotic-resistant strains. As a result, treating these infections has become increasingly difficult. Recently, the FDA approved cefiderocol, a siderophore-antibiotic conjugate, as a new treatment for urinary tract infections (UTIs) caused by antibiotic-resistant Gram-negative bacteria. This approval highlights the potential of targeting the bacterial siderophore-mediated metal uptake process for pharmaceutical interventions. A crucial step in this process involves the uptake of metal-chelated siderophores across the bacterial inner membrane, facilitated by ATP-binding cassette (ABC) importers. Unfortunately, the detailed molecular mechanisms underlying these importers remains poorly understood, impeding the development of targeted drugs. This proposal focuses on a unique example of these critical importers: the yersiniabactin importer YbtPQ from uropathogenic E. coli, the leading cause of UTIs. Our preliminary studies have revealed that YbtPQ exhibits folding characteristics similar to an ABC exporter, representing a novel type of ABC transporter. Building upon this discovery, we expect to study the fundamental structure-function relationship of YbtPQ by pursuing two specific aims: 1) Define the substrate selectivity and inhibitory mechanism of YbtPQ; 2) Understand the unique structural motifs within YbtPQ. To accomplish these goals, we will employ a multidisciplinary approach, combining mutagenesis, specifically-designed transport assays, microscale thermophoresis, circular dichroism, native mass spectrometry, molecular dynamic simulations, and cryo-electron microscopy. Successful completion of this proposal will yield valuable insights into the substrate/inhibitor selectivity and transport dynamics of YbtPQ. This knowledge will serve as a solid foundation for future drug development targeting this importer, offering new possibilities for effectively treating bacterial infections and addressing the challenges of antibiotic resistance.

Key facts

NIH application ID
10877484
Project number
1R01AI177445-01A1
Recipient
UNIVERSITY OF COLORADO DENVER
Principal Investigator
Hongjin Zheng
Activity code
R01
Funding institute
NIH
Fiscal year
2024
Award amount
$499,200
Award type
1
Project period
2024-07-17 → 2025-05-31